Efficacy of Ribociclib Combined with Fulvestrant in the Treatment of Estrogen Receptor/Progesterone Receptor Positive Advanced Breast Cancer
SUN Xiaohu
WANG Kenie
CAO Xuchen
Abstract：Objective:To explore the effects of Ribociclib combined with Fulvestrant in the treatment of patients with estrogen receptor/progesterone receptor(ER/PR)positive advanced breast cancer.Method:A total of 80 ER/PR positive advanced breast cancer patients treated in Tianjin Medical University Cancer Institute and Hospital from February 2022 to February 2024 were selected and randomly divided into control group(n=40)and observation group(n=40)using the random number table method.The control group received Fulvestrant monotherapy,while the observation group received a combination of Ribociclib and Fulvestrant.The short-term efficacy,serum tumor markers levels[cancer antigen 153(CA153)and carcinoembryonic antigen(CEA)],immune function(CD3+,CD4+,CD8+,and CD4+/CD8+),and incidence of adverse reactions during treatment were compared between the two groups.Result:Compared with the control group,the short-term clinical benefit rate of the observation group was higher,the levels of CA153 and CEA were lower,and the immune function level was better,the differences were statistically significant(P<0.05).There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion:Ribociclib combined with Fulvestrant significantly improves the short-term efficacy in patients with ER/PR positive advanced breast cancer,reduces serum tumor marker levels,and enhances immune function without significantly increasing adverse reactions.
Keywords：RibociclibFulvestrantEstrogen receptor positiveProgesterone receptor positiveAdvanced breast cancerTumor markersImmune function
Publication Date：2025-06-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 16-19 )